We observed an increase of RUNX2 by CADD522 in most BC cells, which was regulated via translational and transcriptional regulatory mechanisms, whereas CADD522 had little influence on RUNX1 expression, indicating that CADD522 could overcome a potential drawback derived from specific RUNX2 knock-down or knock-out. Here, RUNX2 is linked to breast cancer.